Detailed Analysis of the Scope and Claims of United States Patent 7,456,168
Introduction
United States Patent 7,456,168, titled "2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones," is a patent that covers a class of compounds useful in treating cell proliferative disorders. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Inventors and Assignees
The patent was invented by a team of researchers including Mark Barvian, Ann Arbor, MI; Richard John Booth, Ann Arbor, MI; John Quin, III, Ann Arbor, MI; Joseph Thomas Repine, Ann Arbor, MI; Derek J. Sheehan, Dexter, MI; Peter Laurence Toogood, Ann Arbor, MI; Scott Norman Vanderwel, Ann Arbor, MI; and Hairong Zhou, Ann Arbor, MI. The assignee of the patent is Warner-Lambert Company, Morris Plains, NJ[4].
Publication and Patent Details
The patent was published on November 25, 2008, and is a continuation of earlier patent applications, including U.S. Ser. No. 11/046,126 and U.S. Ser. No. 10/345,778. It claims the benefit of U.S. Provisional Application No. 60/350,877[4].
Scope of the Invention
Compounds and Their Use
The patent describes a series of substituted 2-aminopyridines, specifically 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones, which are potent inhibitors of cyclin-dependent kinases 4 (cdk4). These compounds are useful in treating cell proliferative disorders, including various types of cancer[4].
Chemical Structure
The compounds are characterized by their specific chemical structure, which includes a pyrido[2,3-d]pyrimidin-7-one backbone with a pyridin-2-ylamino substituent. The detailed description includes methods for preparing these compounds and their intermediates[4].
Claims
The patent includes four claims that define the scope of the invention:
Claim 1
Claim 1 is the broadest claim and describes the general structure of the compounds, including the pyrido[2,3-d]pyrimidin-7-one core and the pyridin-2-ylamino substituent[4].
Claim 2-4
Claims 2-4 are more specific and describe particular embodiments of the compounds, including specific substituents and their positions on the molecular structure. These claims narrow down the scope to specific compounds that are particularly effective as cdk4 inhibitors[4].
Patent Landscape
Related Patents
The patent is part of a larger family of patents related to cyclin-dependent kinase inhibitors. For example, U.S. Patent No. 6,936,612 and U.S. Patent No. 7,208,489 are also part of this family and cover related compounds and their uses[2].
Litigation and Infringement
The patent has been involved in significant litigation, particularly in the context of generic drug manufacturers seeking to produce generic versions of the drug Palbociclib (IBRANCE), which is protected by this and other related patents. Pfizer, the holder of these patents, has engaged in patent infringement lawsuits against several generic drug manufacturers, including Zydus Worldwide DMCC, under the Hatch-Waxman Act[2][5].
Centralization of Litigation
The litigation involving this patent and related patents has been centralized in the District of Delaware due to the common questions of fact and the efficiency of handling multiple cases in one jurisdiction[5].
Strategic Insights
Patent Strength
The strength of the patent can be evaluated using metrics such as citation strength, claim length, technology strength, and litigation likelihood. Tools like the Innography PatentStrength™ score can provide a comprehensive view of the patent's robustness and its impact on future innovations[3].
Blocking Patents
This patent, along with others in the same family, can act as blocking patents that affect the approval of subsequent patent applications. Identifying these patents is crucial for understanding potential legal and market barriers[3].
Forward and Backward Citations
Analyzing forward and backward citations can reveal how this patent influences future innovations and which companies are most frequently citing or being cited by this patent. This analysis provides strategic insights into the competitive landscape[3].
Conclusion
United States Patent 7,456,168 is a significant patent in the field of cancer treatment, particularly for its role in inhibiting cyclin-dependent kinases. The patent's scope and claims are well-defined, covering a specific class of compounds with therapeutic potential. The patent landscape is complex, with ongoing litigation and strategic considerations that highlight its importance in the pharmaceutical industry.
Key Takeaways
- The patent covers substituted 2-aminopyridines as cdk4 inhibitors.
- It is part of a larger family of patents related to cyclin-dependent kinase inhibitors.
- Significant litigation has occurred involving generic drug manufacturers.
- The patent's strength and influence can be evaluated using various metrics.
- Centralization of litigation in the District of Delaware has been ordered.
FAQs
Q: What is the primary use of the compounds described in US Patent 7,456,168?
A: The compounds are primarily used as inhibitors of cyclin-dependent kinases 4 (cdk4) for treating cell proliferative disorders, including cancer.
Q: Who are the inventors and assignees of this patent?
A: The inventors include Mark Barvian, Richard John Booth, and others, with Warner-Lambert Company as the assignee.
Q: What is the significance of the Hatch-Waxman Act in the context of this patent?
A: The Hatch-Waxman Act is relevant because generic drug manufacturers have filed Abbreviated New Drug Applications (ANDAs) challenging the validity of this and related patents, leading to patent infringement lawsuits.
Q: How has the litigation involving this patent been managed?
A: The litigation has been centralized in the District of Delaware to handle multiple cases efficiently.
Q: What tools can be used to evaluate the strength of this patent?
A: Tools such as the Innography PatentStrength™ score can be used to evaluate the patent's strength based on citation strength, claim length, technology strength, and litigation likelihood.
Sources
- US7456168B2 - 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones - Google Patents
- in the united states district court for the district of delaware pfizer inc ... - Insight.RPXCorp
- Unlock Strategic Insights with Our Patent Portfolio Quality Report - HarrityLLP
- (12) United States Patent - Google APIs
- PALBOCICLIB PATENT LITIGATION MDL No. 2912 TRANSFER ORDER - JPML.USCourts
